UPCDC-30245

UPCDC-30245 is an allosteric p97 inhibitor with an IC50 of approximately 27 nM[1]. UPCDC-30245 inhibits the p97 mutant N660K similar to wild type (WT; IC50=300 nM) and shows 3-fold resistance for p97 mutant T688A[2]. UPCDC-30245 can be used in the research of cancer[1][2][3].

Product Specifications

CAS Number

[1883351-01-6]

UNSPSC

12352005

Hazard Statement

H315, H319, H335

Target

P97

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/upcdc-30245.html

Purity

99.85

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

CC(N1CCN(CCNC2CCN(C3=CC=CC(C(N4)=CC5=C4C=CC(F)=C5)=C3)CC2)CC1)C

Molecular Formula

C28H38FN5

Molecular Weight

463.63

Precautions

H315, H319, H335

References & Citations

[1]Banerjee S, et al. 2.3 Å resolution cryo-EM structure of human p97 and mechanism of allosteric inhibition. Science. 2016 Feb 19;351 (6275) :871-5.|[2]Wang F, et al. Allosteric p97 Inhibitors Can Overcome Resistance to ATP-Competitive p97 Inhibitors for Potential Anticancer Therapy. ChemMedChem. 2020 Apr 20;15 (8) :685-694.|[3]Wang F, et al. Temporal proteomics reveal specific cell cycle oncoprotein downregulation by p97/VCP inhibition. Cell Chem Biol. 2021 Nov 23:S2451-9456 (21) 00482-7.